Clinical Trial Update: IL13Ra2-CAR T Cells With or Without Nivolumab and Ipilimumab in Treating Patients With GBM [Phase 1]

View source ↗

Summary

Phase 1 trial evaluating IL13Ra2-CAR T cells with or without nivolumab and ipilimumab in recurrent glioblastoma, currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Glioblastoma

Drugs mentioned

• IL13Ra2-CAR T cells
• ipilimumab (ipilimumab)
• nivolumab (nivolumab)

Snippet

Sponsor: City of Hope Medical Center | Conditions: Recurrent Glioblastoma, Refractory Glioblastoma | Phase 1 | Status: RECRUITING